Should Adjuvant (Protective) Chemotherapy Be Given After Surgery for Gallbladder Cancer?

According to a newly published study in BMC Cancer, adjuvant (protective) chemotherapy significantly prolongs survival in gallbladder cancers if tumor remains after surgery, if the tumor is in its second or third stage, or if spread to neighboring lymph nodes is found in the removed tumor tissue.
Gallbladder cancers are rare cancer types. We rarely detect these tumors at a very early stage. Because cancer is usually not caught early, it is found after it has spread. This is very challenging for physicians in terms of both imaging and treatment. PET scans, liver MRI and conventional CT scans can often mislead us about the extent of tumor spread. For tumors beyond a certain stage, the absence of distant spread (metastasis) and the possibility of surgery are extremely important for treatment. Treatments preventing disease recurrence after surgery are likewise important. Postoperative preventive treatments are actually important for all cancer types. Treatments given to eliminate cells too small to see that have dispersed throughout the body during tumor formation, called micrometastases, are known as adjuvant therapy or protective chemotherapy.
In gallbladder tumors too, how much adjuvant chemotherapy protects against recurrence after complete surgical removal has been debated for years. Various studies have been published on this subject. Evidence for the effectiveness of postoperative adjuvant chemotherapy is somewhat more prominent, and we physicians tend more toward administering chemotherapy. Nevertheless, the issue remains a question in our minds.
BMC Cancer published an extremely comprehensive meta-analysis on this topic. Meta-analysis is an analytical method that pools the main studies performed to date, seeks to explain what they really mean and aims to resolve these questions in our minds; it has the strongest level of evidence.
A total of 243 studies meeting the screening criteria were reviewed. When assessed for study quality, should chemotherapy be given after surgery? was a question that 10 studies had sufficient strength and quality to address. These 10 studies analyzed 3191 patients.
The findings demonstrated that in gallbladder cancer patients, giving chemotherapy after surgery reduces the likelihood of future recurrence and contributes positively to survival .
In summary, looking at the overall group, the survival advantage with protective chemotherapy was found to be minimal. Looking more closely, however, particularly if tumor remained after surgery (what we call a positive surgical margin), if the tumor was beyond the first stage, at stage II. – III., or if spread to neighboring lymph nodes was found in the removed tumor tissue, protective chemotherapy made a survival difference.
This study gave a positive answer to the question “Should chemotherapy be given after surgery?” in gallbladder and bile duct tumors, which had remained uncertain for us. From now on, I too will consider this study when choosing patients for protective chemotherapy after gallbladder or bile duct tumors. If the cancer is beyond the first stage, lymph node involvement is identified in surgical reports, or there is a positive surgical margin even on a millimetric scale, I consider protective chemotherapy appropriate.
Sources
Adjuvant therapy in the treatment of gallbladder cancer: a meta-analysis.
BMC Cancer. 2015 Sep 3;15:615. doi: 10.1186/s12885-015-1617-y.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.